Evidence map›Paper›PMID 42780144›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Signatures of the neutralizing dengue virus-reactive memory B cell repertoire identified by multiplexed envelope dimer probes.

Kelsey E Lowman, Rosemary A Aogo, Sarah Smith, Ysabelle Broderson, Saba Firdous, Gitanjali Bhushan, Devina J Thiono, Patrick Mpingabo, Amy R Henry, Timothy S Johnston and 18 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Kelsey E LowmanViral Epidemiology and Immunology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Rosemary A AogoViral Epidemiology and Immunology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Sarah SmithHuman Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD, USA.
Ysabelle BrodersonViral Epidemiology and Immunology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Saba FirdousViral Epidemiology and Immunology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Gitanjali BhushanViral Epidemiology and Immunology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Devina J ThionoViral Epidemiology and Immunology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Patrick MpingaboViral Epidemiology and Immunology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Amy R HenryHuman Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD, USA.
Timothy S JohnstonHuman Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD, USA.
Jesmine Roberts-TorresHuman Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD, USA.
Luis EstradaHuman Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD, USA.
Chaim A SchrammHuman Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD, USA.
Foo CheungCenter for Human Immunology, Autoimmunity, and Inflammation (CHI), National Institutes of Health, Bethesda, MD, USA.
Jessie J PolancoCenter for Human Immunology, Autoimmunity, and Inflammation (CHI), National Institutes of Health, Bethesda, MD, USA.
Richard AppsCenter for Human Immunology, Autoimmunity, and Inflammation (CHI), National Institutes of Health, Bethesda, MD, USA.
Krista GanglerMedical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Jeffrey I CohenMedical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Sonya JacobsonIntegral Molecular, Philadelphia, PA, USA.
Edgar DavidsonIntegral Molecular, Philadelphia, PA, USA.
Benjamin J DoranzIntegral Molecular, Philadelphia, PA, USA.
James CherryCenter for Human Immunology, Autoimmunity, and Inflammation (CHI), National Institutes of Health, Bethesda, MD, USA.
Iyadh DouagiCenter for Human Immunology, Autoimmunity, and Inflammation (CHI), National Institutes of Health, Bethesda, MD, USA.
Barbara A BlacklawsLab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, UK.
Jonathan L HeeneyLab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, UK.
Aravinda M de SilvaDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA.
Daniel C DouekHuman Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD, USA.
Leah C KatzelnickViral Epidemiology and Immunology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Funding

Project 5: mAb Development Flaviviruses and AlphavirusesU19AI181960 · NIAID · WASHINGTON UNIVERSITY · PI DIAMOND, MICHAEL S, KUHN, RICHARD J. · 2024 to 2024
$46.7M
T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Daniela Weiskopf · 2015 to 2026
$34.1M
NIAID NIH HHS P01 AI106695NIAID NIH HHS U19 AI181960
6 · The paper itself

Abstract

Sequential dengue virus (DENV) infection is thought to induce long-lived protection against dengue. However, little is known about the specificity, phenotype, and repertoire of the enduring B cell response due to limitations in high-throughput methods. We used stabilized DENV envelope (E) dimers as probes for in-depth memory B cell repertoire characterization using two complementary sequencing strategies. Using Rapid Assembly, Transfection, and Production of Immunoglobulins (RATP-Ig), we isolated 227 DENV2 E dimer-specific memory B cells from an immune donor, of which 87% bound at least two serotypes, 68% bound the fusion loop (FL-sensitive), and 42% were neutralizing. Among the most neutralizing, cross-binding antibodies, the FL-sensitive antibodies had weaker but broad neutralization, including to other flaviviruses, whereas FL-'agnostic' antibodies mapped to E domain II and III and were potently neutralizing, but only against one or two serotypes. Competitive binding of the DENV1-4 E dimers distinguished the more potently neutralizing FL-agnostic antibodies and broad and potent anti (α)-envelope dimer epitope (EDE) antibodies from the low-quality FL-sensitive antibodies. Further, analysis of the heavy chain complementarity determining region 3 (CDRH3) showed FL-sensitive and α-EDE antibodies were more negatively charged, but α-EDE antibodies were distinguished by longer and more aromatic CDRH3s. We then demonstrated how oligonucleotide-tagged DENV1-4 dimers and proteogenomic single-cell B cell receptor sequencing (LIBRA-seq) could identify memory B cells predicted to have potent neutralization based on DENV-binding and CDRH3 physiochemical properties. This study provides insight into the secondary DENV-specific B cell repertoire and approaches for identifying protective antibodies as part of large-screening efforts.

Identifiers

PMID42780144
PMCPMC13596526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.